Condition (MeSH)
Urination Disorders
ClinicalTrials.gov lists 2,407 trials for Urination Disorders or a narrower condition beneath it. Coloplast A/S has the most among industry and government lead sponsors, with 27.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
24 of the 2,407 trials are tagged with Urination Disorders itself; the rest are tagged with a narrower condition beneath it.
When did Urination Disorders trials start? (34)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 161
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 123 |
| 2025 | 161 |
| 2024 | 144 |
| 2023 | 140 |
| 2022 | 150 |
| 2021 | 132 |
| 2020 | 121 |
| 2019 | 144 |
| 2018 | 134 |
| 2017 | 120 |
Showing 10 of 34 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 150 trials starting in 2026 and about 160 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 34 months from start to primary completion across 193 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 1,516 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Urination Disorders trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 55 |
| Phase 1/2 | 29 |
| Phase 2 | 170 |
| Phase 2/3 | 31 |
| Phase 3 | 190 |
| Phase 4 | 213 |
| Not applicable | 1,196 |
| Observational | 521 |
| Unknown | 2 |
How many Urination Disorders trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 106 |
| Recruiting | 217 |
| Enrolling by invitation | 19 |
| Active, not recruiting | 81 |
| Completed | 1,364 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Urination Disorders trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Coloplast A/S | 27 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 19 |
| Eli Lilly and Company | 17 |
| Astellas Pharma Inc | 16 |
| Allergan | 14 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Urination Disorders? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Tamsulosin | 21 |
| Tolterodine | 20 |
| Duloxetine | 18 |
| BMS-512148 | 16 |
| Finerenone | 11 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Solifenacin PO | 34 |
| mirabegron OCAS | 27 |
| type A botulinum toxin | 27 |
| Low dose losartan | 19 |
| Desmopresin | 18 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Urination Disorders trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 154 | 38 |
| Osteoarthritis | 90 | 17 |
| Angina Unstable | 86 | 3 |
| Malignant cancer | 79 | 1 |
| SAE by System Organ | 75 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Urination Disorders? (389)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Perineal and Rectal Nerve Recruitment Order Varies During Pudendal Neurostimulator Implant Surgery. | Neurourology and urodynamics | 2025 | Yes |
| Exploring dysfunctional voiding in girls: a comprehensive literature review of assessment and management strategies. | BMC urology | 2025 | Yes |
| Are White Matter Tract Integrities Different in Multiple Sclerosis Women With Voiding Dysfunction? | Female pelvic medicine & reconstructive surgery | 2021 | Yes |
| Altered gut microbiome associated with overactive bladder and daily urinary urgency. | World journal of urology | 2021 | Yes |
| Effect of Denonvilliers' Fascia Preservation Versus Resection During Laparoscopic Total Mesorectal Excision on Postoperative Urogenital Function of Male Rectal Cancer Patients: Initial Results of Chinese PUF-01 Randomized Clinical Trial. | Annals of surgery | 2021 | Yes |
Showing 5 of 389 publications.
Sub-conditions in MeSH (9)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.